Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors

[1]  A. Giobbie-Hurder,et al.  Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis , 2020, Journal for immunotherapy of cancer.

[2]  V. Deshpande,et al.  Immune‐related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies , 2020, Histopathology.

[3]  R. Sullivan,et al.  Budesonide treatment for microscopic colitis from immune checkpoint inhibitors , 2019, Journal of Immunotherapy for Cancer.

[4]  K. Reynolds,et al.  Diagnosis and Management of Rare Immune-Related Adverse Events. , 2019, The oncologist.

[5]  A. Sharpe,et al.  Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. , 2019, Trends in immunology.

[6]  A. Jazaeri,et al.  Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment , 2019, Journal of Immunotherapy for Cancer.

[7]  I. Melero,et al.  Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy , 2019, Nature.

[8]  A. Jazaeri,et al.  Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis , 2019, Journal of Immunotherapy for Cancer.

[9]  U. Moretti,et al.  Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System , 2019, Targeted Oncology.

[10]  Yinghong Wang,et al.  Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab , 2019, Journal of Immunotherapy for Cancer.

[11]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[12]  M. Mino‐Kenudson,et al.  Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis , 2019, Journal of Immunotherapy for Cancer.

[13]  Cheng Zhou,et al.  Pembrolizumab-Induced Immune-Mediated Colitis in a Patient with Concurrent Clostridium Difficile Infection , 2019, Case Reports in Oncology.

[14]  R. Amaria,et al.  Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials , 2019, Therapeutic advances in medical oncology.

[15]  R. Sullivan,et al.  Clinical characterization of colitis arising from anti-PD-1 based therapy , 2018, Oncoimmunology.

[16]  B. Cash,et al.  Excluding irritable bowel syndrome in the inflammatory bowel disease patient: how far to go? , 2019, Current opinion in gastroenterology.

[17]  A. Charabaty,et al.  Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study , 2018, Journal of Immunotherapy for Cancer.

[18]  B. Horst,et al.  Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma. , 2018, Melanoma research.

[19]  B. Helmink,et al.  Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis , 2018, Nature Medicine.

[20]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[21]  R. Amaria,et al.  Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis , 2018, Journal of Immunotherapy for Cancer.

[22]  J. Schachter,et al.  Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case–Control Study , 2018, Cancer Immunology Research.

[23]  C. Lebbé,et al.  Enteritis without colitis in patients treated with immune checkpoint inhibitors: a tricky diagnosis. , 2018, Melanoma research.

[24]  A. Tafreshi,et al.  Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[25]  G. Raju,et al.  Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis , 2018, Journal of Immunotherapy for Cancer.

[26]  R. Bresalier,et al.  Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. , 2018, Inflammatory bowel diseases.

[27]  D. Samuel,et al.  Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. , 2018, Journal of hepatology.

[28]  H. Kluger,et al.  Anti-PD-1 Therapy-Associated Perforating Colitis , 2018, Case reports in gastrointestinal medicine.

[29]  Molly F. Thomas,et al.  Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade , 2018, The oncologist.

[30]  G. Raju,et al.  Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson , 2018, Journal of Immunotherapy for Cancer.

[31]  M. Iwamuro,et al.  Severe Gastritis after Administration of Nivolumab and Ipilimumab , 2018, Case Reports in Oncology.

[32]  J. Szustakowski,et al.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.

[33]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[34]  J. Brahmer,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. , 2018, Journal of oncology practice.

[35]  M. Suarez‐Almazor,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  M. Yeh,et al.  Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury , 2018, Modern Pathology.

[37]  M. Sawyer,et al.  Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  E. Rozeman,et al.  Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management , 2018, ESMO Open.

[39]  D. Samuel,et al.  Liver injury from cancer immunotherapy using monoclonal immune checkpoint inhibitors , 2018 .

[40]  P. Rochaix,et al.  TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma , 2017, Nature Communications.

[41]  M. Suarez‐Almazor,et al.  Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group , 2017, Journal of Immunotherapy for Cancer.

[42]  M. Dougan.  Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract , 2017, Front. Immunol..

[43]  J. Gómez-Reino,et al.  Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. , 2017, Seminars in arthritis and rheumatism.

[44]  J. Andrews,et al.  Infliximab for ipilimumab‐induced colitis: A series of 13 patients , 2017, Asia-Pacific journal of clinical oncology.

[45]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[46]  Dana Pe’er,et al.  Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade , 2017, Cell.

[47]  C. Garbe,et al.  Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins. , 2017, European journal of cancer.

[48]  N. Bhala,et al.  Systematic review with meta‐analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection , 2017, Alimentary pharmacology & therapeutics.

[49]  E. Plimack,et al.  Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  K. Kerr,et al.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  K. Kerr,et al.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  J. Andrews,et al.  Systematic review with meta‐analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis , 2017, Alimentary pharmacology & therapeutics.

[53]  G. Lauwers,et al.  Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies , 2017, The American journal of surgical pathology.

[54]  J. Boike,et al.  Severe Esophagitis and Gastritis from Nivolumab Therapy , 2017, ACG case reports journal.

[55]  F. Hodi,et al.  Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients , 2017, Cancer Immunology Research.

[56]  A. Carneiro,et al.  Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis , 2017, Cancer Immunology, Immunotherapy.

[57]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2017, Cell.

[58]  J. Misdraji,et al.  Fibrin Ring Granulomas in Checkpoint Inhibitor-induced Hepatitis. , 2017, The American journal of surgical pathology.

[59]  A. Hauschild,et al.  Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. , 2016, The New England journal of medicine.

[60]  M. Brown,et al.  Vedolizumab: a novel treatment for ipilimumab-induced colitis , 2016, BMJ Case Reports.

[61]  M. Suarez‐Almazor,et al.  Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports , 2016, PloS one.

[62]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[63]  D. Planchard,et al.  Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. , 2016, Journal of Crohn's & colitis.

[64]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.

[65]  A. Pommer,et al.  Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis , 2016, Oncoimmunology.

[66]  P. Rutgeerts,et al.  Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. , 2016, The New England journal of medicine.

[67]  T. Jaffe,et al.  Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis , 2016, Abdominal Radiology.

[68]  G. Thomas,et al.  Infliximab for IPILIMUMAB-Related Colitis—Letter , 2015, Clinical Cancer Research.

[69]  Amitabh Srivastava,et al.  Ipilimumab-associated Hepatitis: Clinicopathologic Characterization in a Series of 11 Cases , 2015, The American journal of surgical pathology.

[70]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[71]  Yuehong Chen,et al.  Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses , 2015, Clinical Rheumatology.

[72]  A. Franke,et al.  Early-onset Crohn’s disease and autoimmunity associated with a variant in CTLA-4 , 2014, Gut.

[73]  A. Schäffer,et al.  Autosomal-dominant immune dysregulation syndrome in humans with CTLA4 mutations , 2014, Nature Medicine.

[74]  J. B. Oliveira,et al.  Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4 , 2014, Science.

[75]  Kristin Stephens,et al.  Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.

[76]  A. Shinagare,et al.  Ipilimumab-associated colitis: CT findings. , 2013, AJR. American journal of roentgenology.

[77]  Tsung-Teh Wu,et al.  Association between ipilimumab and celiac disease. , 2013, Mayo Clinic proceedings.

[78]  S. Tirumani,et al.  Ipilimumab associated hepatitis: imaging and clinicopathologic findings , 2013, Investigational New Drugs.

[79]  P. Friedlander,et al.  Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma , 2013, Melanoma research.

[80]  D. Kleiner,et al.  Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma , 2012, Digestive Diseases and Sciences.

[81]  E. Szigethy,et al.  Inflammatory bowel disease. , 2011, Pediatric clinics of North America.

[82]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[83]  A. Maraveyas,et al.  A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma , 2009, Clinical Cancer Research.

[84]  Judy H Cho,et al.  Inflammatory bowel disease. , 2009, The New England journal of medicine.

[85]  M. Gordon.  Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4 , 2008 .

[86]  A. Feldman,et al.  Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  I. Panagiotou,et al.  Malignant melanoma metastatic to the gastrointestinal tract , 2002, Melanoma research.

[88]  P. Nickerson,et al.  CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. , 1997, Journal of immunology.